AI Article Synopsis
- - The global incidence of Chronic Myeloid Leukemia (CML) is around 100,000 new cases annually, posing a significant health challenge.
- - Since the introduction of Tyrosine Kinase Inhibitors (TKIs) in 2000, mortality rates among CML patients have greatly decreased, though over 25% still need to switch medications during treatment for various reasons.
- - The down-regulation of a specific gene, which acts as a tumor suppressor in other cancers, is notable in CML patients, prompting discussions about its potential as a therapeutic target in treatment strategies.
Article Abstract
The worldwide CML incidence expects 100,000 patients every year thus representing a substantial health burden. A year 2000 is notable year, where Tyrosine kinase inhibitors (TKIs) had been introduced to the CML treatment plan. However, despite the dramatically reduce in mortality rate of CML patients due to TKIs, still over 25% of CML patients need to switch TKIs at least once during treatment timeline for many reasons. On the other hand, behave as a tumor suppressor gene in different neoplasms and is strongly down-regulated in CML patients. We discussed briefly in series of articles the possible reasons of it is down regulation. Here, we discuss its role as potential therapeutic target in treatment plan.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677154 | PMC |
| http://dx.doi.org/10.1177/10732748221140201 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!